-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MsHYVYOIL2IgjBKps18iZsa3+2SpC3RxmR2TvLILWH+OD+2jTo23XFdtDA8iVQKp
 KTRTfX1RL18UI6L+ctJn0w==

<SEC-DOCUMENT>0001075880-05-000015.txt : 20050225
<SEC-HEADER>0001075880-05-000015.hdr.sgml : 20050225
<ACCEPTANCE-DATETIME>20050225063738
ACCESSION NUMBER:		0001075880-05-000015
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20050216
FILED AS OF DATE:		20050225
DATE AS OF CHANGE:		20050225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		05638845

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc0502252.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 25 February, 2005  By /s/Ronald Lea Erratt Company Secretary


ASX & MEDIA RELEASE
25 FEBRUARY, 2004

NOVOGEN SALES UP, SIGNIFICANT ADVANCES WITH CLINICAL TRIAL PROGRAM

Half year results for pharmaceutical company, Novogen Limited
(ASX: NRT, NASDAQ: NVGN), reflect improved sales for the half
year to 31 December, 2004, and a marginal increase in expenditure
due to significant advances with human clinical trialling of its
lead anti-cancer drug phenoxodiol.

Cash reserves at 31 December, 2004, stood at $48 million.

Sales for the half year were $7.3 million, up six per cent
from $6.9 million for the half year ending 31 December, 2003.

Total revenue for the half year was up 4.4 per cent to
$9.59 million compared with the previous corresponding period.

Royalties of approximately A$1.1 million also were received
during the half year under Novogen's soy patent licence
agreement with Solae LLC, a joint venture between DuPont
and Bunge.  During February, it was announced that Novogen
had agreed to the assignment of the licence from Solae
to the larger company Archer Daniels Midland in the US.

Net loss for the half year was up $0.53 million to
$4.69 million, compared with $4.16 million for the
same period last year.

Novogen Chief Executive Officer, Mr Christopher Naughton
said marketing and selling expense savings of
$1.9 million over the previous corresponding period were
achieved with more targeted marketing of consumer products
but were offset by costs associated with the rapidly
expanding drug development program.

The Novogen Group's leading anti-cancer drug phenoxodiol
is in Phase ll human clinical trials for the treatment
of prostate and ovarian cancers and in addition is in
trials for renal cancer and cervical cancer, all through
its 86.9 per cent owned US subsidiary, Marshall Edwards, Inc.

Phenoxodiol has also achieved "fast track" development status
from the US Food and Drug Administration for use
in both oral and intravenous forms for the treatment
of various cancers.

This means phenoxodiol has been made eligible for
certain accelerated marketing approval programs
although it does not guarantee regulatory approval.
Phase III trials are now in planning.

During January, Yale University School of Medicine research
also revealed phenoxodiol enhanced the ability of
another cancer drug to kill human ovarian cancer cells
in the laboratory.


Mr Naughton said Novogen's ongoing strategy was to
continue self-funding its drug development program for
as long as was commercially viable.

"Our present cash reserve position ensures that we
can resist the need to prematurely seek outside
partnerships for drug development and pharmaceutical
licensing.  We will however invoke our licensing
plan " Mr Naughton said.

Novogen is focused on research and development
of drugs derived from its phenolic technology platform.
The Company manages its international research
and development programs utilising the expertise
and clinical research capabilities of
universities and hospitals in Australia, the US
and other key international locations.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
